CA2075340A1 - Spongy material consisting essentially of hyaluronic acid or its derivatives, and its use in microsurgery - Google Patents
Spongy material consisting essentially of hyaluronic acid or its derivatives, and its use in microsurgeryInfo
- Publication number
- CA2075340A1 CA2075340A1 CA002075340A CA2075340A CA2075340A1 CA 2075340 A1 CA2075340 A1 CA 2075340A1 CA 002075340 A CA002075340 A CA 002075340A CA 2075340 A CA2075340 A CA 2075340A CA 2075340 A1 CA2075340 A1 CA 2075340A1
- Authority
- CA
- Canada
- Prior art keywords
- hyaluronic acid
- derivatives
- spongy material
- consisting essentially
- ranging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 47
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 47
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 47
- 239000000463 material Substances 0.000 title claims abstract description 41
- 238000002406 microsurgery Methods 0.000 title claims abstract description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 10
- 230000007170 pathology Effects 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000000859 sublimation Methods 0.000 claims description 2
- 230000008022 sublimation Effects 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000008439 repair process Effects 0.000 abstract description 39
- 239000000126 substance Substances 0.000 abstract description 5
- 238000011049 filling Methods 0.000 abstract description 4
- 210000004400 mucous membrane Anatomy 0.000 abstract description 2
- 230000037309 reepithelialization Effects 0.000 abstract description 2
- 230000006641 stabilisation Effects 0.000 abstract description 2
- 238000011105 stabilization Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 43
- 206010052428 Wound Diseases 0.000 description 24
- 208000027418 Wounds and injury Diseases 0.000 description 24
- 210000003454 tympanic membrane Anatomy 0.000 description 14
- 241000700159 Rattus Species 0.000 description 12
- 210000000959 ear middle Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000003902 lesion Effects 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 229920000609 methyl cellulose Polymers 0.000 description 8
- 239000001923 methylcellulose Substances 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010033109 Ototoxicity Diseases 0.000 description 2
- 206010045210 Tympanic Membrane Perforation Diseases 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000000883 ear external Anatomy 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 231100000262 ototoxicity Toxicity 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- KIUKXJAPPMFGSW-YXBJCWEESA-N (2s,4s,5r,6s)-6-[(2s,3r,5s,6r)-3-acetamido-2-[(3s,4r,5r,6r)-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@@H]3[C@@H]([C@@H](O)C(O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)C(C(O)=O)O1 KIUKXJAPPMFGSW-YXBJCWEESA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 101150034533 ATIC gene Proteins 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000201841 Celosia Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 229920000704 biodegradable plastic Polymers 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- HIDUXZXZQUHSBT-UHFFFAOYSA-N ethenol;formaldehyde Chemical compound O=C.OC=C HIDUXZXZQUHSBT-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000037313 granulation tissue formation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002459 porosimetry Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/28—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2201/00—Foams characterised by the foaming process
- C08J2201/04—Foams characterised by the foaming process characterised by the elimination of a liquid or solid component, e.g. precipitation, leaching out, evaporation
- C08J2201/05—Elimination by evaporation or heat degradation of a liquid phase
- C08J2201/0504—Elimination by evaporation or heat degradation of a liquid phase the liquid phase being aqueous
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/07—Microporous membranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Materials Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Polymers & Plastics (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI912207A IT1251151B (it) | 1991-08-05 | 1991-08-05 | Materiale spugnoso essenzialmente costituito da acido ialuronico,o suoi derivati |
| ITMI91A002207 | 1991-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2075340A1 true CA2075340A1 (en) | 1993-02-06 |
Family
ID=11360538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002075340A Abandoned CA2075340A1 (en) | 1991-08-05 | 1992-08-05 | Spongy material consisting essentially of hyaluronic acid or its derivatives, and its use in microsurgery |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5503848A (OSRAM) |
| EP (1) | EP0526865A1 (OSRAM) |
| JP (1) | JPH05255124A (OSRAM) |
| KR (1) | KR930003921A (OSRAM) |
| AU (1) | AU654027B2 (OSRAM) |
| BR (1) | BR9203032A (OSRAM) |
| CA (1) | CA2075340A1 (OSRAM) |
| IT (1) | IT1251151B (OSRAM) |
| MX (1) | MX9204517A (OSRAM) |
| TW (1) | TW215903B (OSRAM) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1260154B (it) * | 1992-07-03 | 1996-03-28 | Lanfranco Callegaro | Acido ialuronico e suoi derivati in polimeri interpenetranti (ipn) |
| IT1263144B (it) * | 1993-02-04 | 1996-08-01 | Lanfranco Callegaro | Composizioni farmaceutiche comprendenti materiale spugnoso costituito da derivati esterei dell'acido ialuronico in associazione con altre sostanze farmacologicamente attive |
| US6080092A (en) * | 1994-10-06 | 2000-06-27 | Xomed Surgical Products, Inc. | Industrial cleaning sponge |
| US6130264A (en) | 1994-10-06 | 2000-10-10 | Xomed Surgical Products, Inc. | Synthetic sponge and surgical spear comprising synthetic sponge |
| IT1282207B1 (it) * | 1995-11-20 | 1998-03-16 | Fidia Advanced Biopolymers Srl | Sistemi di coltura di cellule staminali di midollo osseo umano in matrici tridimensionali costituiti da esteri dell'acido ialuronico |
| US6099952A (en) * | 1998-02-18 | 2000-08-08 | Xomed Surgical Products, Inc. | Medical sponge having mucopolysaccharide coating |
| US5976150A (en) * | 1998-08-25 | 1999-11-02 | Alcon Laboratories, Inc. | Intraocular lens injection system |
| US6120484A (en) * | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
| AU2002230102B9 (en) | 2001-01-31 | 2008-05-01 | Seikagaku Corporation | Crosslinked polysaccharide sponge |
| US7923431B2 (en) | 2001-12-21 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
| PL217885B1 (pl) * | 2002-08-07 | 2014-08-29 | Medidom Lab | Sposób wytwarzania sterylnej, gotowej do użycia, wodnej formulacji farmaceutycznej, zawierającej sól wysokocząsteczkowego kwasu hialuronowego |
| PL377477A1 (pl) * | 2002-12-11 | 2006-02-06 | Ferrosan A/S | Materiały na bazie żelatyny jako waciki |
| AR054637A1 (es) * | 2004-01-30 | 2007-07-11 | Ferrosan As | Aerosoles y composiciones hemostaticas |
| EP1786480B1 (en) * | 2004-07-09 | 2016-09-21 | Ferrosan Medical Devices A/S | Haemostatic composition comprising hyaluronic acid |
| JP2006342207A (ja) * | 2005-06-07 | 2006-12-21 | Toshiba Corp | 発泡材料組成物、発泡材料、および発泡材料の再生方法 |
| WO2008027904A2 (en) * | 2006-08-28 | 2008-03-06 | Rexaderm, Inc. | Dry wound dressing and drug delivery system |
| US8257455B2 (en) | 2007-07-30 | 2012-09-04 | Korea Institute Of Machinery & Materials | Plasma burner and diesel particulate filter trap |
| JP5569398B2 (ja) * | 2008-02-29 | 2014-08-13 | フェッローサン メディカル ディバイス エー／エス | 止血および／または創傷治癒を促進するための装置 |
| KR20190026056A (ko) | 2008-04-21 | 2019-03-12 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| US8030297B2 (en) * | 2008-05-14 | 2011-10-04 | Otonomy, Inc. | Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders |
| US8648119B2 (en) * | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
| US8846770B2 (en) | 2008-06-18 | 2014-09-30 | Otonomy, Inc. | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders |
| US8349353B2 (en) * | 2008-06-27 | 2013-01-08 | Otonomy, Inc. | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders |
| WO2010011466A2 (en) | 2008-06-27 | 2010-01-28 | Otonomy, Inc. | Controlled-release cns modulating compositions and methods for the treatment of otic disorders |
| WO2010008995A2 (en) * | 2008-07-14 | 2010-01-21 | Otonomy, Inc. | Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders |
| US8496957B2 (en) * | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
| AU2009274229B2 (en) * | 2008-07-21 | 2013-08-22 | Otonomy, Inc. | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
| US8399018B2 (en) * | 2008-07-21 | 2013-03-19 | Otonomy, Inc. | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders |
| US8784870B2 (en) * | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
| US8318817B2 (en) | 2008-07-21 | 2012-11-27 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
| US20100016450A1 (en) * | 2008-07-21 | 2010-01-21 | Otonomy, Inc. | Controlled release delivery devices for the treatment of otic disorders |
| JP2012506436A (ja) | 2008-10-22 | 2012-03-15 | ハウス イアー インスティトゥート | 代謝型グルタミン酸受容体の調節による内耳の疾病の処置および／または予防 |
| EP2474569A4 (en) * | 2009-09-02 | 2014-03-19 | Terumo Corp | POROUS STRUCTURE |
| CA2865349C (en) | 2012-03-06 | 2021-07-06 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
| RU2636240C2 (ru) | 2012-06-12 | 2017-11-21 | Ферросан Медикал Дивайсиз А/С | Сухая гемостатическая композиция |
| US20150252120A1 (en) | 2012-10-09 | 2015-09-10 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Modified hyaluronic acid derivatives and use thereof |
| BR112015030612B1 (pt) | 2013-06-21 | 2020-07-21 | Ferrosan Medical Devices A/S | método para preparar uma composição seca |
| MX2016002408A (es) | 2013-08-27 | 2016-10-28 | Otonomy Inc | Metodos para el tratamiento de trastornos oticos pediatricos. |
| CA2928963C (en) | 2013-12-11 | 2020-10-27 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
| WO2016058612A1 (en) | 2014-10-13 | 2016-04-21 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
| CA2970710A1 (en) | 2014-12-24 | 2016-06-30 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
| EP3316930B1 (en) | 2015-07-03 | 2019-07-31 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
| US10842741B2 (en) | 2016-07-27 | 2020-11-24 | Ritapharma, Co., Ltd. | Oral mucosa application material and method for producing same therefor |
| EP3512513A4 (en) | 2016-09-16 | 2020-04-15 | Otonomy, Inc. | OTIC GEL FORMULATIONS FOR THE TREATMENT OF EXTERNAL OTITIS |
| EP3790600B1 (en) | 2018-05-09 | 2023-12-27 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2915309A1 (de) * | 1979-04-14 | 1980-10-30 | Behringwerke Ag | Verfahren zur bestimmung von anti-hyaluronidase und hierfuer verwendbares mittel |
| US4490351A (en) * | 1982-03-15 | 1984-12-25 | Children's Hospital Medical Center | Methods of treating disorders of an eye with liquid perfluorocarbons |
| DE3482812D1 (de) * | 1983-10-11 | 1990-08-30 | Fidia Spa | Fraktionen von hyaluronsaeure mit pharmazeutischer aktivitaet, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen. |
| IL74715A0 (en) * | 1984-03-27 | 1985-06-30 | Univ New Jersey Med | Biodegradable matrix and methods for producing same |
| SE8501022L (sv) * | 1985-03-01 | 1986-09-02 | Pharmacia Ab | Format alster och forfarande for dess framstellning |
| US4851521A (en) * | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| DK505488D0 (da) * | 1987-12-21 | 1988-09-09 | Bar Shalom Daniel | Middel og anvendelse af samme |
| FR2650180B1 (fr) * | 1989-07-31 | 1995-03-03 | Chisso Corp | Procede de production d'une feuille facilement soluble dans l'eau a base d'acide hyaluronique ou de hyaluronate et feuille ainsi obtenue |
-
1991
- 1991-08-05 IT ITMI912207A patent/IT1251151B/it active IP Right Grant
-
1992
- 1992-08-03 EP EP92113212A patent/EP0526865A1/en not_active Ceased
- 1992-08-03 TW TW081106130A patent/TW215903B/zh active
- 1992-08-04 MX MX9204517A patent/MX9204517A/es unknown
- 1992-08-04 KR KR1019920013969A patent/KR930003921A/ko not_active Withdrawn
- 1992-08-04 JP JP4207881A patent/JPH05255124A/ja active Pending
- 1992-08-04 BR BR929203032A patent/BR9203032A/pt not_active Application Discontinuation
- 1992-08-05 AU AU20840/92A patent/AU654027B2/en not_active Ceased
- 1992-08-05 US US07/925,073 patent/US5503848A/en not_active Expired - Lifetime
- 1992-08-05 CA CA002075340A patent/CA2075340A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IT1251151B (it) | 1995-05-04 |
| BR9203032A (pt) | 1993-03-30 |
| US5503848A (en) | 1996-04-02 |
| AU2084092A (en) | 1993-02-11 |
| ITMI912207A1 (it) | 1993-02-05 |
| TW215903B (OSRAM) | 1993-11-11 |
| JPH05255124A (ja) | 1993-10-05 |
| AU654027B2 (en) | 1994-10-20 |
| KR930003921A (ko) | 1993-03-22 |
| ITMI912207A0 (it) | 1991-08-05 |
| MX9204517A (es) | 1993-03-01 |
| EP0526865A1 (en) | 1993-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5503848A (en) | Spongy material consisting essentially of hyaluronic acid or its derivatives, and its use in microsurgery | |
| Shi et al. | Naturally derived dual dynamic crosslinked multifunctional hydrogel for diabetic wound healing | |
| Raisi et al. | Preparation, characterization, and antibacterial studies of N, O-carboxymethyl chitosan as a wound dressing for bedsore application | |
| Hafezi et al. | 3D printed chitosan dressing crosslinked with genipin for potential healing of chronic wounds | |
| CN104321085B (zh) | 氧化再生纤维素止血粉末及制备方法 | |
| JP2960204B2 (ja) | 高水和された自己支持フィルムの形態のゲル | |
| EP3151872B1 (en) | Wound dressing | |
| EP0772463B1 (en) | Alginate fibre, process for the preparation thereof and use | |
| TWI445555B (zh) | 含積雪草活性成分之敷材及其應用 | |
| US4074713A (en) | Poly(N-acetyl-D-glucosamine) products | |
| EP3569260A1 (en) | Non-woven fabric bandage and a method for the production of a non-woven fabric bandage | |
| DE69330727T2 (de) | Gefriergetrockneter Verband | |
| US10111783B1 (en) | Silica fiber composition and method of use | |
| EP0682534A1 (en) | Pharmaceutical compositions comprising a spongy material consisting of ester derivatives of hyaluronic acid combined with other pharmacologically active substances | |
| US20230293779A1 (en) | Silica fiber compositions and methods of use | |
| Nour et al. | Angiogenic effect of a nanoniosomal deferoxamine-loaded poly (vinyl alcohol)–Egg white film as a promising wound dressing | |
| Wyrwa et al. | Electrospun mucosal wound dressings containing styptics for bleeding control | |
| CN115624655B (zh) | 壳聚糖-氧化海藻酸钠水凝胶材料及其制备方法和应用 | |
| CN106110369B (zh) | 一种医用复合型透明质酸敷料及其制备方法 | |
| MX2008000969A (es) | Biomateriales a base de carboximetilcelulosa salificada con zinc asociado con derivados de acido hialuronico. | |
| EP0772465B1 (en) | Alginate fibres, manufacture and use | |
| Mathias‐Santamaria et al. | Silk‐fibroin chitosan film for palatal wounds: Material development, in vitro study, and pilot clinical trial | |
| CN116983287A (zh) | 一种促进外伤创面修复的美洲大蠊贴膜剂及其制备方法和应用 | |
| Venzin et al. | Biocompatibility of pegylated fibrinogen and its effect on healing of full-thickness skin defects: a preliminary study in rats | |
| Khokhlenkova | Prospects of using biopolymeric films in medicine and pharmacy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |